Drugs / citrate

Trials 8 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT03114722 Jul 2017 → Jul 2018 vascular occlusion disorder National University Hospital, Singapore Unknown No outcome recorded
Phase 31 trial
Phase 3 NCT05814341 Jul 2023 → Dec 2024 Assistance Publique - Hôpitaux de Paris Completed No outcome recorded
Phase 45 trials
Phase 4 NCT06807905 Feb 2019 → Sep 2020 end stage renal failure University Medical Centre Ljubljana Completed No outcome recorded
Phase 4 NCT03035812 Feb 2017 → Feb 2020 metabolic acidosis, nephrolithiasis Jean-Philippe Bertocchio Completed No outcome recorded
Phase 4 NCT02669589 Mar 2016 → Apr 2019 acute kidney injury University Hospital Muenster Completed No outcome recorded
Phase 4 NCT02860299 Feb 2015 → Jan 2016 acute kidney injury Centre Hospitalier Universitaire Dijon Completed No outcome recorded
Phase 4 NCT00294502 Sep 2003 → May 2004 end stage renal failure Henry Ford Health System Completed No outcome recorded
Phase not applicable1 trial
NCT02194569 Jul 2014 → Jun 2017 acute kidney injury Ziekenhuis Oost-Limburg Completed No outcome recorded
Also used as a comparator or background therapy in 4 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial
Phase 3 NCT01483872 Comparator Mar 2012 → Sep 2013 University of California, San Diego Terminated No outcome recorded
Phase 42 trials
Phase 4 NCT02868697 Background Nov 2013 → Aug 2015 Hamad Medical Corporation Completed No outcome recorded
Phase 4 NCT00286273 Comparator Mar 2003 → Jan 2008 acute kidney injury Onze Lieve Vrouwe Gasthuis Completed No outcome recorded
Phase not applicable1 trial
NCT07366372 Background May 2023 → Nov 2024 Tanta University Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as citrate “Oral alkalization with sodium bicarbonate (NaHCO3 ) or citrate is prescribed for conditions ranging from metabolic acidosis to nephrolithiasis.” PMID 34564842 Oct 2021
11

“taurolidine citrate, 4% citrate /25000 IU unit urokinase (TauroLock U25000” NCT02868697

NCT02860299

NCT01483872

NCT05814341

NCT00294502

NCT03114722

NCT00286273

NCT07366372

NCT02194569

NCT06807905

NCT02669589

Known as Dirinco Citra-Lock 4% “use of 4% citrate lock (Dirinco Citra-Lock 4%)” NCT03114722
Action Inhibit “Citrate chelates ionised calcium in blood, inhibiting calcium-dependent clotting pathways.” NCT03114722
Route Other “a Heparin or Citrate Lock is Injected” NCT02860299